CPhI Russia Returns to Moscow

Article

The conference will gather more than 3000 attendees from 64 countries.

CPhI Russia returns to Moscow from March 28–30, 2017. The event will gather more than 3000 attendees from 64 countries, and 199 exhibitors to network and do business with pharma ingredients, manufacturers, packaging experts, and machining specialists in the region. Attendees will gain in-depth insights from the International Forum, a dedicated matchmaking program, speaker sessions, and other networking opportunities. The program includes detailed analysis on compulsory licensing, drugs labeling, and modern assortment solutions and global trends in the pharmaceutical packaging industry. CPhI Russia offers a matchmaking service that allows companies to meet with relevant partners during the show–it also enables sellers to become buyers as they see new potential suppliers.

According to CPhI, the partnerships and deals struck at CPhI Russia have helped establish Russia at the forefront of pharmerging markets and it is expected to reach a value of $31.2 billion by 2019. This, coupled with a government commitment to invest nearly $5 billion in funding to bring existing manufacturing sites to GMP standards, is driving increased interest in the event. Under the new plan, foreign investment is also encouraged through a fast-track approval process and tax incentives.

“We are seeing a steady growth in three main areas driven by a gentrifying healthcare sector, a rising local population, and government support for domestic manufacturing. Currency variation aside, the pharma market is growing at just under 10% year-on-year and distributers, APIs manufacturers, and machinery providers are seeing high demand across Russia and CIS countries. Traditionally, Russia has been a hard market to enter and that is why CPhI Russia has become so intertwined with the market’s growth,” said Orhan Caglayan, brand director at CPhI Russia in a statement.

Source: CPhI Russia

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content